CELL & GENE THERAPY PRODUCTS
MANUFACTURING, QUALITY AND REGULATORY CONSIDERATIONS
EUROPE 2025

KNOWLEDGE SHARING AND **CAPACITY BUILDING**

- It is ***crucial to elucidate the MoA and control potency*** with a matrix of release and characterisation assays which can be complemented by the overall control strategy.
- Analytical tools and models using big data and AI approaches are ***developing towards end-to-end integrated control*** of ATMP manufacture.
- ***Understanding genetic stability and the effect of gene modifiers*** is an ongoing need.
- We must make sure that clinicians and patients ***understand ATMP risks against the back-drop of risks*** associated with more established treatments.

CGTP EUROPE 2025 **BY THE NUMBERS**

First-Time Attendees

38

Regulators Participated

22

Company Participation

46

Country Participation

17

Austria | Belgium | Finland | France | Germany | India | Ireland | Italy | Japan | Netherlands | Saudi Arabia | Spain | Sweden | Switzerland | Thailand | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. **www.casss.org**

CASSS™
SHARING SCIENCE **SOLUTIONS**